Related Experiment Video

Updated: Mar 24, 2026

In Vivo Real-Time Study of Drug Effects on Carotid Blood Flow in the Ovine Fetus
11:59

In Vivo Real-Time Study of Drug Effects on Carotid Blood Flow in the Ovine Fetus

Published on: April 28, 2023

682

Effects of systemic propranolol treatment on physical growth of patients with infantile hemangiomas

Li Hu1, Bingrui Zhou2, Huizhen Huang1

  • 1Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

The Journal of Dermatology
|March 7, 2016
PubMed

Insights

Systemic propranolol is a safe treatment for infantile hemangiomas, with minor complications. The therapy did not significantly impact infants

Area of Science:

  • Pediatric dermatology
  • Pharmacology

Background:

  • Infantile hemangiomas are common vascular tumors in infants.
  • Propranolol has been a primary treatment since 2008.

Purpose of the Study:

  • To evaluate complications of systemic propranolol therapy.
  • To assess the impact on infant physical growth.

Main Methods:

  • 76 infants received propranolol (2 mg/kg/day).
  • Abnormal symptoms and growth parameters were monitored.
  • Follow-up extended to age 2 years.

Main Results:

  • Minor complications included sleep issues, diarrhea, and glucose changes.
  • 5.26% showed a growth curve drop; half normalized post-treatment.
  • No long-term underweight, wasting, or stunning observed.

Conclusions:

  • Systemic propranolol is safe for problematic infantile hemangiomas.
  • The treatment does not adversely affect physical growth.
  • Monitoring for minor side effects is recommended.

Keywords:
complicationsgrowth curveinfantile hemangiomasphysical growthpropranolol

More Related Videos

Measuring Cardiac Autonomic Nervous System ANS Activity in Children09:45

Measuring Cardiac Autonomic Nervous System ANS Activity in Children

Published on: April 29, 2013

21.6K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.3K

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.9K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
595
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.9K
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
458